Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MVA Smallpox vaccine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | Previously vaccinated for smallpox, 1x10-8 dose |
| B | EXPERIMENTAL | Smallpox vaccine naive, 1x10-8 dose |
| C | EXPERIMENTAL | Previous smallpox vaccination, 1x10-7 dose |
| D | EXPERIMENTAL | Smallpox vaccine naive, 1x10-7 dose |
| E | EXPERIMENTAL | Previous smallpox vaccination, 1x10-6 dose |
| F | EXPERIMENTAL | Smallpox vaccine naive, 1x10-6 dose |
| G | EXPERIMENTAL | Previous smallpox vaccination, placebo dose |
| H | EXPERIMENTAL | Smallpox vaccine naive, placebo dose |
| Name | Type | Description |
|---|---|---|
| MVA Smallpox vaccine | DRUG | Two 0.5mL subcutaneous injections, separated by 28 days |
| Placebo | DRUG | Two 0.5mL subcutaneous injections, separated by 28 days |
Inclusion Criteria: * subjects must be in good general health, checked on toxicity grading table. * for previously vaccinated subjects- must be between the ages of 33 and 55 with a previous vaccine more than 10 years ago. * for vaccine naive subjects- must be between the ages of 18 and 32, and have...
MVA Smallpox vaccine is an investigational vaccine being developed for protection against smallpox, an infectious disease caused by the variola virus. It is a modified vaccinia Ankara (MVA) based vaccine candidate. Sanofi is developing this vaccine, which has been studied in a Phase 2 clinical trial.
MVA Smallpox vaccine is intended for the prevention of smallpox. It is designed to induce an immune response against the variola virus. The vaccine is being developed by Sanofi and has completed a Phase 2 trial in healthy volunteers.
MVA Smallpox vaccine is being developed by Sanofi, a global pharmaceutical company. Sanofi trades on the New York Stock Exchange under the ticker symbol SNY. The vaccine candidate is part of Sanofi's infectious disease portfolio.
MVA Smallpox vaccine is in Phase 2 of clinical development. A Phase 2 trial has been completed, but the vaccine is not yet approved. It remains an investigational product and further studies would be needed to support potential regulatory approval.
MVA Smallpox vaccine has been evaluated in a completed Phase 2 clinical trial, NCT00466245. This study assessed the safety, tolerability, and immunogenicity of three dose levels of the ACAM3000 Smallpox Vaccine. It enrolled 590 healthy volunteers aged 18 years and older and was randomized, double-blind, and controlled.